Fig. 8

DC661 combined with sorafenib resulted in maximal tumor growth suppression in HCC tumor models. A Response of Hep 1-6-SR cell derived HCC tumors to treatment with DC661 (3 mg/kg/d), sorafenib (30 mg/kg/d), or both drugs (DC661 3 mg/kg/d, sorafenib 30 mg/kg/d). The tumor after 21 days of treatment is shown. Scale bar, 1 cm. B Graph showing the volume of tumors after 21 days of treatment; ***P < 0.001, Mann-Whitney U test. C Waterfall plot showing the response of each tumor after 21 days; ***P < 0.001, Mann-Whitney U test. D Graph showing the weight of tumors after 21 days of treatment; ***P < 0.001, Mann-Whitney U test. E Immunohistochemical images of LC3B and P62 in resected tumors. Scale bar, 20 μm. F H&E staining for pathological changes in tumor sections (top row). TUNEL staining (green) for apoptosis in tumor sections (bottom row). Blue fluorescence indicates the cell nuclei. Scale bar, 20 μm. G Survival curves for four groups of tumor-bearing mice given different treatments (n = 12 per group); ***P < 0.001, Log-rank test